ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for AML patients: Heart-Safe drug combo enters trials
Disease control Not yet recruitingThis study tests a three-drug combination (aclarubicin, azacitidine, venetoclax) for people with acute myeloid leukemia (AML), including those newly diagnosed or whose cancer has returned. The goal is to find the safest dose and see if the combo improves remission rates. About 11…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 26, 2026 04:19 UTC
-
New hope for hard-to-treat leukemia: experimental combo targets patients who failed standard therapy
Disease control Not yet recruitingThis study tests a new combination of three drugs (lisafotoclax, decitabine, and homoharringtonine) in 35 adults with acute myeloid leukemia (AML) whose cancer did not respond to or could not tolerate a common first treatment. The goal is to see if this new mix can shrink or elim…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New oral drug combo aims to tame tough leukemia
Disease control Not yet recruitingThis study tests an oral form of cladribine combined with two other drugs (low-dose cytarabine and venetoclax) in people with acute myeloid leukemia (AML). The first part finds the safest dose; the second part checks if that dose helps control the disease. About 58 adults with re…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New transplant recipe aims to cut Graft-Versus-Host disease in blood cancer patients
Disease control Not yet recruitingThis early-phase study tests a new combination of chemotherapy drugs (thiotepa, busulfan, fludarabine) followed by a lower dose of post-transplant cyclophosphamide for stem cell transplants in people with blood cancers like leukemia and myelodysplastic syndrome. The goal is to re…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Sawa Ito, MD • Aim: Disease control
Last updated May 26, 2026 04:14 UTC
-
New Triple-Drug attack shows promise against tough blood cancer
Disease control Not yet recruitingThis study tests a new combination of three drugs (venetoclax, azacitidine, and mitoxantrone liposome) against the standard two-drug therapy for adults newly diagnosed with acute myeloid leukemia (AML). About 204 participants aged 18 to 65 will be randomly assigned to receive eit…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
New cell therapy trial offers hope for young leukemia patients
Disease control Not yet recruitingThis early-stage trial tests a new treatment called CART123 for children and young adults (up to age 29) with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target and kill leukem…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New hope for Hard-to-Treat leukemia: Three-Drug combo targets relapsed AML
Disease control Not yet recruitingThis study tests a combination of three drugs (cladribine, low-dose cytarabine, and venetoclax) in people whose acute myeloid leukemia (AML) has come back or not responded to prior treatment, especially those who have already tried a venetoclax-based regimen. The goal is to see i…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
New triple therapy aims to boost leukemia remission in seniors
Disease control Not yet recruitingThis study tests whether adding a third drug, homoharringtonine, to the standard two-drug treatment (venetoclax and azacitidine) can improve remission rates in older adults (ages 60-75) newly diagnosed with acute myeloid leukemia (AML). About 308 participants will be randomly ass…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE3 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
Can blood cancer patients safely stop anti-rejection drugs sooner?
Disease control Not yet recruitingThis study tests whether patients who receive a stem cell transplant for blood cancers can safely stop the anti-rejection drug tacrolimus earlier than usual. The goal is to reduce side effects while still preventing graft-versus-host disease (GVHD). About 50 participants will be …
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New blood test may personalize leukemia treatment, avoiding harsh chemo
Disease control Not yet recruitingThis study tests a new blood test (5hmC) to see how well acute myeloid leukemia (AML) is responding to treatment. About 112 adults with newly diagnosed AML will get either a milder drug (hypomethylating agent) or standard strong chemo. The test helps doctors decide if more treatm…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New hope for older AML patients: 3-Drug combo shows promise in early trial
Disease control Not yet recruitingThis study tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor (G-CSF) in 61 older or frail adults newly diagnosed with acute myeloid leukemia (AML) who cannot tolerate standard intensive chemotherapy. The goal is to see if thi…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE2 • Sponsor: First People's Hospital of Hangzhou • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
Massive data project aims to crack the code of childhood leukemia relapse
Knowledge-focused Not yet recruitingThis study will combine medical and genetic information from 2000 children with acute myeloid leukemia (AML) across France. The goal is to identify rare patient groups at high risk of relapse and find new ways to improve survival. No new treatments are tested; instead, researcher…
Matched conditions: ACUTE MYELOID LEUKEMIA (AML)
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC